jose baselga
jose baselga
Unknown affiliation
No verified email
Title
Cited by
Cited by
Year
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
DJ Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, ...
New England journal of medicine 344 (11), 783-792, 2001
117462001
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, ...
New England Journal of Medicine 353 (16), 1659-1672, 2005
54582005
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner, PM Harari, J Giralt, N Azarnia, DM Shin, RB Cohen, CU Jones, ...
New England Journal of Medicine 354 (6), 567-578, 2006
53062006
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ...
Journal of clinical oncology 21 (12), 2237-2246, 2003
37042003
The landscape of somatic copy-number alteration across human cancers
R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ...
Nature 463 (7283), 899-905, 2010
29942010
Trastuzumab emtansine for HER2-positive advanced breast cancer
S Verma, D Miles, L Gianni, IE Krop, M Welslau, J Baselga, M Pegram, ...
New England Journal of Medicine 367 (19), 1783-1791, 2012
26712012
Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer
J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ...
New England Journal of Medicine 366 (6), 520-529, 2012
25982012
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, ...
Cancer research 66 (3), 1500-1508, 2006
25392006
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
J Baselga, J Cortés, SB Kim, SA Im, R Hegg, YH Im, L Roman, JL Pedrini, ...
New England Journal of Medicine 366 (2), 109-119, 2012
22632012
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
20542014
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash …
JA Bonner, PM Harari, J Giralt, RB Cohen, CU Jones, RK Sur, D Raben, ...
The lancet oncology 11 (1), 21-28, 2010
18872010
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
M Yu, A Bardia, BS Wittner, SL Stott, ME Smas, DT Ting, SJ Isakoff, ...
science 339 (6119), 580-584, 2013
18502013
Systematic identification of genomic markers of drug sensitivity in cancer cells
MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ...
Nature 483 (7391), 570-575, 2012
18502012
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
J Baselga, D Tripathy, J Mendelsohn, S Baughman, CC Benz, L Dantis, ...
Journal of clinical oncology 14 (3), 737-744, 1996
17621996
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ...
The lancet 369 (9555), 29-36, 2007
17302007
The EGF receptor family as targets for cancer therapy
J Mendelsohn, J Baselga
Oncogene 19 (56), 6550-6565, 2000
16162000
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn, J Baselga
Journal of clinical oncology 21 (14), 2787-2799, 2003
16132003
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
14492015
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
A Carracedo, L Ma, J Teruya-Feldstein, F Rojo, L Salmena, A Alimonti, ...
The Journal of clinical investigation 118 (9), 3065-3074, 2008
14202008
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing …
MD Pegram, A Lipton, DF Hayes, BL Weber, JM Baselga, D Tripathy, ...
Journal of clinical oncology 16 (8), 2659-2671, 1998
13181998
The system can't perform the operation now. Try again later.
Articles 1–20